Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19252300 | ALLELE, MOLECULAR MARKER, AND PRIMER PAIR OF RICE HPS1 GENE, AND APPLICATIONS THEREOF | June 2025 | December 2025 | Allow | 6 | 2 | 0 | Yes | No |
| 18999227 | METHODS FOR TREATING NEUROBLASTOMA | December 2024 | January 2026 | Allow | 13 | 3 | 0 | Yes | No |
| 18636932 | EX VIVO METHOD FOR THE PROGNOSIS OF METASTASIS IN PROSTATE CANCER | April 2024 | March 2026 | Abandon | 23 | 0 | 1 | No | No |
| 18430518 | METHYLATION CLASSIFIER FOR DETECTION OF HPV-INDUCED INVASIVE CANCERS, NONHPV-INDUCED GYNAECOLOGICAL AND ANOGENITAL CANCERS AND THEIR HIGH-GRADE PRECURSOR LESIONS | February 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18517748 | Extracellular mRNA Markers of Muscular Dystrophies in Human Urine | November 2023 | May 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18508945 | DETECTING GASTRIC NEOPLASM | November 2023 | January 2026 | Allow | 26 | 1 | 1 | Yes | No |
| 18489096 | DETECTING NEOPLASM | October 2023 | July 2025 | Allow | 21 | 1 | 2 | No | No |
| 18366436 | METHOD OF PREDICTING RISK OF RECURRENCE OF CANCER | August 2023 | October 2025 | Allow | 26 | 1 | 1 | No | No |
| 18230601 | METHODS FOR TREATING NEUROBLASTOMA | August 2023 | May 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18130547 | DNA Methylation and Mutational Analysis Methods for Bladder Cancer Surveillance | April 2023 | December 2025 | Allow | 32 | 3 | 1 | No | No |
| 18159218 | DETECTING BABESIA SPECIES NUCLEIC ACID IN A SAMPLE | January 2023 | April 2025 | Allow | 27 | 2 | 0 | No | No |
| 18153927 | COMPOSITIONS AND METHODS FOR DETECTION OF MYCOPLASMA GENITALIUM | January 2023 | July 2025 | Allow | 30 | 1 | 1 | No | No |
| 18015885 | KITS AND METHODS USING COMBINED SAMPLES TO IMPROVE SENSITIVITY | January 2023 | March 2026 | Allow | 38 | 0 | 1 | Yes | No |
| 18152127 | METHODS OF DETECTING AND TYPING PATHOGENIC STRAINS OF FRANCISELLA TULARENSIS | January 2023 | February 2025 | Allow | 25 | 1 | 1 | No | No |
| 18090439 | COMPOSITIONS AND METHODS FOR OBTAINING PLANT CULTIVARS WITH DESIRED TERPENE PROFILES BASED ON TERPENE SYNTHASE GENE SELECTION | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18069550 | DETECTING COLORECTAL NEOPLASIA | December 2022 | April 2025 | Allow | 28 | 3 | 2 | No | No |
| 18066693 | METHOD OF PREDICTING RISK OF RECURRENCE OF CANCER | December 2022 | April 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18065369 | COMPOSITIONS TO DETECT ADENOVIRUS NUCLEIC ACIDS | December 2022 | October 2025 | Abandon | 34 | 0 | 0 | No | No |
| 18009943 | Methods for detecting and predicting cancer | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17979538 | CHROMOSOMAL ASSESSMENT TO DIFFERENTIATE HISTIOCYTIC MALIGNANCY FROM LYMPHOMA AND HEMANGIOSARCOMA IN DOGS | November 2022 | July 2025 | Allow | 33 | 1 | 0 | Yes | Yes |
| 17973055 | DETECTION UNITS AND METHODS FOR DETECTING A TARGET ANALYTE | October 2022 | January 2025 | Allow | 26 | 1 | 1 | Yes | No |
| 17919435 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION IN FILAMENTOUS FUNGAL CELLS | October 2022 | December 2025 | Allow | 38 | 2 | 0 | Yes | No |
| 17914689 | CBX6 AS EPIGENETIC MARKER FOR THE IDENTIFICATION OF IMMUNE CELLS, IN PARTICULAR MEMORY B CELLS | September 2022 | March 2026 | Allow | 41 | 2 | 0 | Yes | No |
| 17943483 | METHOD FOR BARLEY HYBRID SEED PRODUCTION | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17910858 | ADENO-ASSOCIATED VIRUS VECTOR AND USE THEREOF | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17929563 | COMPOSITION FOR DETECTING PATHOGENS, AND KIT AND METHOD THEREFOR | September 2022 | February 2026 | Allow | 42 | 1 | 1 | No | No |
| 17929508 | ASSAYS AND METHODS FOR MISCARRIAGE RISK ASSESSMENT | September 2022 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17904352 | Novel Y-Chromosomal Short Tandem Repeat Markers for Typing Male Individuals | August 2022 | December 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17877830 | MARKERS TO PREDICT MACROCYCLIC LACTONE DRUG RESISTANCE IN DIROFILARIA IMMITIS, THE CAUSATIVE AGENT OF HEARTWORM DISEASE | July 2022 | April 2025 | Allow | 33 | 1 | 1 | No | No |
| 17796024 | DETERMINATION OF QUALITY AND ORIGIN OF FISH BY EPIGENETICS | July 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17758470 | METHODS OF DETERMINING PTEN COPY NUMBER | July 2022 | March 2026 | Abandon | 44 | 1 | 0 | No | No |
| 17728240 | METHOD FOR ASSESSING PROGNOSIS OR RISK STRATIFICATION OF LIVER CANCER BY USING CPG METHYLATION VARIATION IN GENE | April 2022 | December 2025 | Abandon | 43 | 3 | 0 | No | No |
| 17718025 | Polynucleotides for the Amplification and Detection of Chlamydia Trachomatis | April 2022 | September 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17633746 | Selective Covalent Capture of a DNA Sequence | February 2022 | August 2025 | Allow | 43 | 1 | 1 | No | No |
| 17561404 | SHRIMP DISEASE DETECTION ASSAYS AND USES THEREOF | December 2021 | July 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17557556 | COLORECTAL CANCER SCREENING METHOD AND DEVICE | December 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17554362 | Methods and Devices for Obtaining Cellular and DNA Material from Human Female Reproductive System | December 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17620261 | Predicting Chronic Allograft Injury Through Age-Related DNA Methylation | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17620230 | METHODS AND COMPOSITIONS FOR COMPREHENSIVE AND HIGH SENSITIVITY DETECTION OF PATHOGENS AND DRUG RESISTANCE MARKERS | December 2021 | November 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17617899 | DETERMINATION OF AN INFECTION PROFILE IN AN INDIVIDUAL AND USES THEREOF | December 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17526498 | METHODS, KITS, AND DEVICES FOR DIAGNOSING, PROGNOSING, AND TREATING PSYCHIATRIC DISORDERS IN A PATIENT | November 2021 | June 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17523482 | METHOD TO PREDICT THE PATTERN OF LOCOMOTION IN HORSES | November 2021 | April 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17502894 | METHODS FOR REDUCING DRUG-INDUCED LIVER INJURY | October 2021 | April 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17472118 | ANALYTICAL METHOD AND KIT | September 2021 | March 2026 | Abandon | 54 | 3 | 1 | Yes | No |
| 17436485 | METHYLATION STATUS OF GASDERMIN E GENE AS CANCER BIOMARKER | September 2021 | October 2025 | Abandon | 49 | 1 | 0 | Yes | No |
| 17464175 | METHODS FOR TREATING DISEASE AND REDUCING DRUG-INDUCED LIVER INJURY IN PATIENT POPULATIONS | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17410383 | DETECTING ESOPHAGEAL DISORDERS | August 2021 | February 2025 | Allow | 42 | 1 | 0 | No | No |
| 17409129 | COMPOSITIONS AND METHODS FOR PERFORMING METHYLATION DETECTION ASSAYS | August 2021 | January 2025 | Allow | 41 | 1 | 1 | No | No |
| 17396581 | METHODS, SYSTEMS, AND KITS FOR TREATING INFLAMMATORY DISEASE TARGETING IL18R1 | August 2021 | August 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17393836 | BIOMARKERS FOR DIAGNOSING BREAST CANCER AND USES THEREOF | August 2021 | January 2026 | Abandon | 53 | 3 | 0 | Yes | No |
| 17383390 | GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET | July 2021 | April 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17423751 | CANID MICROBIOME MONITORING TOOLS AND DIAGNOSTIC METHODS | July 2021 | December 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17423708 | MONITORING TOOLS AND DIAGNOSTIC METHODS | July 2021 | December 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17423663 | MONITORING AND DIAGNOSTIC METHODS FOR FELINE MICROBIOME CHANGES | July 2021 | February 2026 | Abandon | 55 | 3 | 1 | No | No |
| 17423727 | MONITORING TOOLS AND DIAGNOSTIC METHODS FOR DETERMINING A CANID'S MICROBIOME AGE STATUS | July 2021 | February 2026 | Abandon | 55 | 4 | 1 | No | No |
| 17362273 | DNA METHYLATION AND GENOTYPE SPECIFIC BIOMARKER FOR PREDICTING POST-TRAUMATIC STRESS DISORDER | June 2021 | December 2024 | Allow | 42 | 1 | 0 | No | No |
| 17360692 | GENETIC TEST FOR LIVER COPPER ACCUMULATION IN DOGS | June 2021 | October 2024 | Allow | 39 | 1 | 1 | No | No |
| 17415881 | Method of Diagnosing Gastric Cancers Using MicroRNAs | June 2021 | February 2026 | Abandon | 56 | 3 | 1 | No | No |
| 17347027 | DETECTING PANCREATIC HIGH-GRADE DYSPLASIA | June 2021 | March 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17346709 | METHODS AND KITS FOR CLASSIFYING CANNABINOID PRODUCTION IN CANNABIS PLANTS | June 2021 | April 2025 | Allow | 46 | 2 | 0 | No | No |
| 17336935 | DETECTION OF CLDN18-ARHGAP6 FUSION GENE OR CLDN18-ARHGAP26 FUSION GENE IN PANCREATIC CANCER | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17335526 | METHODS FOR DIAGNOSING AND TREATING CANCER BY MEANS OF THE EXPRESSION STATUS AND MUTATIONAL STATUS OF NRF2 AND DOWNSTREAM TARGET GENES OF SAID GENE | June 2021 | March 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17334683 | METHODS OF DETECTING AND TREATING MULTIPLE SYSTEM ATROPHY | May 2021 | October 2025 | Allow | 53 | 3 | 2 | Yes | No |
| 17291458 | TEPOXALIN TARGETING OF ABCB1 OVEREXPRESSING CANCERS | May 2021 | January 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17228749 | ASSAYS FOR DETECTING MULTIPLE TICK-BORNE PATHOGENS | April 2021 | June 2025 | Allow | 50 | 2 | 1 | No | No |
| 17225405 | Solute Carrier Family 14 Member 1 (SLC14A1) Variants And Uses Thereof | April 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17281223 | EGG-TYPE CHICKEN WHOLE-GENOME SNP CHIP AND USE THEREOF | March 2021 | December 2024 | Allow | 44 | 1 | 0 | No | No |
| 17216170 | METHODS OF MAST CELL TUMOR PROGNOSIS AND USES THEREOF | March 2021 | August 2024 | Allow | 41 | 1 | 0 | No | No |
| 17205796 | DETECTING BREAST CANCER | March 2021 | February 2025 | Allow | 47 | 1 | 0 | No | No |
| 17204227 | COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID | March 2021 | April 2025 | Allow | 49 | 6 | 1 | Yes | No |
| 17201403 | CROSS-ASSEMBLY PHAGE DNA SEQUENCES, PRIMERS AND PROBES FOR PCR-BASED IDENTIFICATION OF HUMAN FECAL POLLUTION SOURCES | March 2021 | December 2024 | Allow | 45 | 2 | 0 | No | No |
| 17179990 | PANCREATIC CANCER | February 2021 | March 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17178110 | DETECTING BREAST CANCER | February 2021 | October 2025 | Allow | 56 | 4 | 0 | No | No |
| 17257319 | PRIMERS, KITS AND METHODS FOR THE DETECTION AND QUANTITATION OF CABLE BACTERIA (CANDIDATUS ELECTRONEMA) | December 2020 | May 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17112608 | METHOD TO PREDICT HERITABLE CANINE NON-CONTACT CRUCIATE LIGAMENT RUPTURE | December 2020 | August 2024 | Allow | 45 | 2 | 0 | No | No |
| 16979832 | METHOD FOR PREDICTING AND MONITORING RESPONSE TO AN IMMUNE CHECKPOINT INHIBITOR | September 2020 | June 2025 | Abandon | 57 | 5 | 1 | No | No |
| 15733039 | METHOD FOR DETERMINING THE RESPONSE OF A MALIGNANT DISEASE TO AN IMMUNOTHERAPY | April 2020 | November 2024 | Abandon | 55 | 6 | 1 | Yes | No |
| 16725195 | METHOD TO DIAGNOSE MALIGNANT MELANOMA IN THE DOMESTIC DOG | December 2019 | August 2024 | Allow | 56 | 3 | 0 | No | Yes |
| 16718945 | Methods for Identifying a Companion Animal at Risk of Calcium Oxalate Stone Formation and Treatments and Compositions for Reducing the Risk | December 2019 | April 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16616640 | IDENTIFICATION OF EPIGENETIC SIGNATURES INDICATING CEREBRAL PALSY | November 2019 | December 2022 | Abandon | 37 | 3 | 1 | No | No |
| 16659095 | CHROMOSOMAL ASSESSMENT TO DIAGNOSE UROGENITAL MALIGNANCY IN DOGS | October 2019 | January 2025 | Allow | 60 | 4 | 0 | Yes | Yes |
| 16495070 | MGMT EPIGENETIC DEEP-SEQUENCING ASSAY | September 2019 | March 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16560210 | COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO A SUBSTANCE USE DISORDER | September 2019 | December 2025 | Abandon | 60 | 11 | 1 | No | No |
| 16484791 | LIQUID BIOPSIES FOR DETECTION OF PROSTATE CANCER | August 2019 | March 2025 | Abandon | 60 | 7 | 1 | Yes | No |
| 16481956 | METHOD FOR INDICATING A PRESENCE OR NON-PRESENCE OF PROSTATE CANCER IN INDIVIDUALS WITH PARTICULAR CHARACTERISTICS | July 2019 | June 2025 | Abandon | 60 | 7 | 1 | No | No |
| 16466460 | METHOD FOR DIAGNOSING A SKIN DISPLAYING SIGNS OF DRYNESS | June 2019 | June 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16428622 | Methods For Single-Molecule Fluorescence Amplification Of RNA | May 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | Yes |
| 16265631 | SYSTEMS AND METHODS FOR TRACKING THE ORIGIN OF CANNABIS PRODUCTS AND CANNABIS DERIVATIVE PRODUCTS | February 2019 | March 2023 | Abandon | 50 | 5 | 1 | Yes | No |
| 16315609 | LIVER CANCER METHYLATION MARKERS AND USES THEREOF | January 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16315608 | COLON CANCER METHYLATION MARKERS AND USES THEREOF | January 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16315610 | LUNG CANCER METHYLATION MARKERS AND USES THEREOF | January 2019 | March 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16092436 | METHODS FOR LUNG CANCER DETECTION | October 2018 | August 2024 | Allow | 60 | 6 | 1 | No | No |
| 16088247 | METHOD OF DETECTING INHERITED EQUINE MYOPATHY | September 2018 | July 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 16086714 | METHODS FOR DETECTING BORDETELLA | September 2018 | June 2025 | Allow | 60 | 10 | 1 | No | No |
| 15964883 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF | April 2018 | March 2020 | Allow | 22 | 1 | 1 | Yes | No |
| 15952912 | BIOAGENT DETECTION OLIGONUCLEOTIDES | April 2018 | January 2020 | Allow | 21 | 4 | 2 | Yes | No |
| 15806148 | CpG ISLAND METHYLATION PROFILE IN NON-INVASIVE ORAL RINSE SAMPLES FOR DETECTION OF ORAL AND PHARYNGEAL CARCINOMA | November 2017 | September 2025 | Allow | 60 | 7 | 1 | Yes | Yes |
| 15589257 | METHODS FOR DETECTING ENHANCED NMDA RECEPTOR FUNCTION AND USES THEREOF | May 2017 | April 2018 | Allow | 11 | 1 | 1 | Yes | No |
| 15519503 | DNA METHYLATION STATUS AS A BIOMARKER OF ALCOHOL USE AND ABSTINENCE | April 2017 | November 2025 | Abandon | 60 | 14 | 1 | No | No |
| 15300859 | METHODS AND KITS FOR IDENTIFYING PRE-CANCEROUS COLORECTAL POLYPS AND COLORECTAL CANCER | September 2016 | May 2019 | Allow | 31 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GOLDBERG, JEANINE ANNE.
With a 80.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GOLDBERG, JEANINE ANNE works in Art Unit 1682 and has examined 227 patent applications in our dataset. With an allowance rate of 84.1%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.
Examiner GOLDBERG, JEANINE ANNE's allowance rate of 84.1% places them in the 59% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by GOLDBERG, JEANINE ANNE receive 2.53 office actions before reaching final disposition. This places the examiner in the 74% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by GOLDBERG, JEANINE ANNE is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +11.8% benefit to allowance rate for applications examined by GOLDBERG, JEANINE ANNE. This interview benefit is in the 47% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 20.9% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.0% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 85.3% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 72.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 76.2% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 24.7% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.3% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.